Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 3/20 | 0.44 |
| ▸ | MMP9 | P14780 | 3/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954534 | 0.83 | CA2 (0.46) | GPR84CA2FFAR1BIRC2 | |
| SCHEMBL2952253 | 0.83 | CA2 (0.46) | GPR84CA2FFAR1BIRC2 | |
| SCHEMBL22304191 | 0.83 | CA2 (0.46) | GPR84CA2FFAR1BIRC2 | |
| SCHEMBL5063316 | 0.83 | GPR84 (0.42) | MMP3MMP9MMP1GPR84CA2 | |
| SCHEMBL8101019 | 0.83 | GPR84 (0.42) | MMP3MMP9MMP1GPR84CA2 | |
| SCHEMBL2374648 | 0.83 | GPR84 (0.42) | MMP3MMP9MMP1GPR84CA2 | |
| Hydrochloric Acid SCHEMBL8139506 | 0.79 | MMP3 (0.45) | MAPTMMP3MMP9MMP1GPR84 | |
| SCHEMBL23430580 | 0.78 | EPHX1 (0.56) | GPR84CA2GRIK1GRIK2BIRC2 | |
| SCHEMBL29205059 | 0.78 | CA2 (0.41) | GPR84CA2FFAR1BIRC2 | |
| SCHEMBL29205057 | 0.78 | CA2 (0.41) | GPR84CA2FFAR1BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | SYMRISE GMBH & CO. KG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-1816998-B1 | FORMULATIONS COMPRISING CERAMIDES AND/OR PSEUDOCERAMIDES AND (ALPHA-)BISABOLOL FOR COMBATING SKIN DAMAGE | SYMRISE GMBH & CO KG (DE) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286102-A1 | Formulations comprising ceramides and/or pseudoceramides and (alpha-)bisabolol for combating skin damage | CERT1, CERS2, SGMS1 | MAPT 967/4885SMN1; SMN2 2809/4885MMP3 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.